Evidence map›Paper›PMID 37060392›Full record

ReviewClinical hematology international2023

Current Advances in Multiple Myeloma: A Post International Myeloma Society (IMS 2022) Round Table Debate by the International Academy for Clinical Hematology (IACH).

Nizar J Bahlis, Luciano J Costa, Thierry Facon, Jean-Luc Harousseau, Salomon Manier, Aurore Perrot, Cyrille Touzeau, Mohamad Mohty

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical hematology international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Nizar J BahlisUniversity of Calgary, Calgary, AB, Canada.
Luciano J CostaDivision of Hematology/Oncology, O'Neal Comprehensive Cancer Center at University of Alabama at Birmingham, University of Alabama at Birmingham, Birmingham, AL, USA.
Thierry FaconUniversity Hospital of Lille, University of Lille, Lille, France.
Jean-Luc HarousseauInstitut de Cancerologie de l'Ouest, Centre René Gauducheau, Nantes-St Herblain, France.
Salomon ManierUniversity Hospital of Lille, University of Lille, Lille, France.
Aurore PerrotService d'Hématologie, CHU de Toulouse-Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France.
Cyrille TouzeauDepartment of Hematology, University Hospital Hôtel-Dieu, Nantes, France.
Mohamad MohtySorbonne University, Service d'Hématologie Clinique Et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, INSERM UMRs938, Paris, France. mohamad.mohty@inserm.fr.ORCID http://orcid.org/0000-0002-7264-808X
Université de Lille · FRCentre Hospitalier Universitaire de Toulouse · FRInserm · FRInstitut de Cancérologie de l'Ouest · FRUniversity of Alabama at Birmingham · USUniversity of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This round table discussion organized by the International Academy for Clinical Hematology (IACH) was dedicated to the 19th annual meeting of the International Myeloma Society (IMS), which was held in Los Angeles between the 25th and 27th August 2022. After some key meetings of the discipline of the field of clinical hematology, the IACH organizes regular round table discussion in order to summarize the flow of information and get the opinion of a panel of experts and the key take-home messages. As part of this discussion, the panellists debated 6 key topics: disease monitoring, management of high-risk multiple myeloma (MM), induction for newly-diagnosed MM, management of relapsed MM, immune reconstitution, and vaccination and cellular therapy in MM.

Indexed as

ImmumotherapyMultiple myelomaStem cell transplantation

Identifiers

PMID37060392
PMCPMC10241743
OpenAlexW4365811103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.